<DOC>
	<DOCNO>NCT00751556</DOCNO>
	<brief_summary>To determine pharmacokinetic profile extend release tablet naproxen sodium 660 mg relative establish commercial Aleve 220 mg tablet follow single dose administration steady-state follow multiple dose administration 4 day .</brief_summary>
	<brief_title>Single/Multiple Dose Bioavailability Trial</brief_title>
	<detailed_description />
	<mesh_term>Naproxen</mesh_term>
	<criteria>Healthy , ambulatory , male female volunteer 18 55 year age BMI approximately 18 30 kg/m2 , total body weight &gt; 50 kg ( 110Ibs ) History hypersensitive aspirin ( ASA ) , naproxen sodium , acetaminophen , similar pharmacological agent component product History gastrointestinal bleeding perforation relate previous NonSteroidal AntiInflammatory Drug ( NSAID ) therapy Active , history current peptic ulcer/hemorrhage ( two distinct episode proven ulceration bleeding ) Have take ASA , ASAcontaining product , acetaminophen ( acetylparaaminophenol APAP ) NSAID ( OTC prescription ) 7 day prior dose treatment period , study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Naproxen Sodium</keyword>
	<keyword>Bioavailability</keyword>
</DOC>